Lixte Biotechnology Holdings, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 6.31 million compared to USD 6.73 million a year ago. Basic loss per share from continuing operations was USD 4 compared to USD 5 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.49 USD | +6.50% | +7.79% | +5.96% |
02:30pm | LIXTE Biotechnology Holdings, Inc. Announces Executive Changes | CI |
09/05 | Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
+5.96% | 52.59L | |
+48.64% | 5.46TCr | |
-6.44% | 3.99TCr | |
+37.07% | 3.88TCr | |
+14.28% | 2.69TCr | |
-11.17% | 2.62TCr | |
-21.40% | 1.88TCr | |
+25.64% | 1.22TCr | |
+0.96% | 1.22TCr | |
+27.04% | 1.19TCr |
- Stock Market
- Equities
- LIXT Stock
- News Lixte Biotechnology Holdings, Inc.
- Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022